Despite the impact menopause can have on the skin, Galderma’s research reveals that the topic remains largely overlooked in the wider menopause conversation, leaving many women unaware of the role hormonal changes may be playing in the aesthetic changes they see in their skin.^1,2 More than half of women (56%) initially interpreted these changes as signs of ageing, while only 29% connected them to menopause.¹ One in two women remain unaware that hormonal fluctuations during perimenopause and menopause can have a significant impact on skin, underscoring the need for greater education in this area.¹ This misread is also influencing skincare purchases: 70% have bought products designed to address signs of ageing because they believed they would help with skin changes experienced during perimenopause or menopause.¹ Finding the right information can be challenging too: 62% of women have felt overwhelmed by skincare advice during the menopause or perimenopause, with almost half of those struggling to find clear information saying advice was too general and focused on ageing rather than menopause.¹ There is a clear appetite for greater clarity, with over 80% of women agreeing that better understanding the difference between general ageing and menopause-related skin changes would help them feel more informed and in control of their skincare decisions.¹New clinical data identify optimized injectable aesthetics treatment protocol for menopause-induced skin changes New results from an eight-month investigator-initiated trial (IIT) supported by Galderma and conducted by Dr. Andreas Nikolis, both on the face and the décolletage, demonstrated that the combination of Restylane Skinboosters and Sculptra delivered sustained improvements in skin hydration, quality, remodeling, as well as patient satisfaction in menopausal women.² Patients were divided into two groups and treated with either Restylane Skinboosters-first, Sculptra-second, or Sculptra-first, Restylane Skinboosters-second.² Women treated with Restylane Skinboosters-first, followed by Sculptra, demonstrated an earlier visible clinical response and greater dermal remodeling, with facial dermal thickness increasing by 27.3% compared with 15.7% in the Sculptra-first, Restylane Skinboosters-second group, highlighting the value of preconditioning the skin to maximize regenerative outcomes.² “This first-of-its-kind clinical study provides compelling evidence that sequencing treatments can deliver significantly greater benefits than either approach alone in menopausal skin. By first using Restylane Skinboosters to rapidly improve hydration and optimize the skin microenvironment, followed by Sculptra to stimulate collagen production and progressive tissue remodeling, more favorably, we are now able to address both the immediate and longer-term biologic changes associated with menopause. The result is a strongly supported scientific treatment strategy that combines rapid improvement in hydration with sustained enhancement in skin quality and remodeling, while achieving high levels of patient satisfaction. These findings provide clinicians with a new evidence-based framework for treating menopausal skin.”